Rory Shallis, MD

Cancer Focus:
Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndromes (MDS)

Dr. Shallis received his MD degree from Rutgers-Robert Wood Medical School, Piscataway, New Jersey. He completed an Internal Medicine Residency at Brown University-Rhode Island Hospital, Providence, followed by a Hematology-Oncology Fellowship at Yale University-New Haven Hospital, Connecticut. Dr. Shallis joins us from Yale University School of Medicine, where he was an Assistant Professor in the Section of Hematology, Department of Internal Medicine.

Dr. Shallis’s clinical interests focus on the care of patients with myeloid malignancies and acute leukemias, particularly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). His research interests center on clinical investigation for patients with myeloid malignancies, particularly clinical trials of novel agents and combination therapies.

Clinical Trial 23594
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Eganelisib ()
Status: Open

Clinical Trial 23602
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: AUTX-703 ()
Status: Open

Clinical Trial 23750
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); GDC-0199 (Venetoclax); Venetoclax (); Ziftomenib/Placebo (); daunorubicin ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Iqbal U, Fadul J, Sallman DA, Shallis RM. Menin inhibitors for adult acute myeloid leukemia: 2025 update. Expert Opin Inv Drug. 2026 Jan.35(1):37-48. Pubmedid: 41474933.
• Hunter CJ, Im AP, Shallis RM. Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. Cancers (Basel). 2026 Jan.18(2). Pubmedid: 41595195. Pmcid: PMC12838703.
• Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M. Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities. Haematologica. 2026 Jan. Pubmedid: 41609030.
• Joshi U, Shallis RM. Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. Biomedicines. 2026 Jan.14(1). Pubmedid: 41595753. Pmcid: PMC12838656.
• Joshi U, Shallis RM. MECOM-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies. Hematol Rep. 2025 Oct.17(6). Pubmedid: 41283235. Pmcid: PMC12642003.
• Wang R, Stempel JM, Shallis RM, Huntington SF, Zeidan AM, Neparidze N, Di M, Bewersdorf JP, Mendez L, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia. 2025 Nov.2(4):100159. Pubmedid: 41216598. Pmcid: PMC12597058.
• Bewersdorf JP, Hasle V, Shallis RM, Thompson E, Lopes de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox BA, Zeidan AM. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Ther Adv Hematol. 2025 Jun.16. Pubmedid: 40546817. Pmcid: PMC12182606.
• Moseley A, LeBlanc M, Freidlin B, Shallis RM, Zeidan AM, Sallman DA, Erba HP, Little RF, Othus M. Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials. Clin Trials. 2025 Jun.22(3):361-366. Pubmedid: 39815460. Pmcid: PMC12143638.
• Getz TM, Bewersdorf JP, Kewan T, Stempel JM, Bidikian A, Shallis RM, Stahl M, Zeidan AM. Beyond HMAs: Novel Targets and Therapeutic Approaches. Semin Hematol. 2024 Dec.61(6):358-369. Pubmedid: 39389839.
• Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec.99(12):2388-2391. Pubmedid: 39253997.